Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Index Funds median (366 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 01 Feb 2022 – 20 Aug 2026, limited by UTI BSE Sensex Index Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | UTI BSE Sensex Index Fund | Nifty 50 |
|---|---|---|
| 01 Feb 2022 | ₹100.00 | ₹100.00 |
| 19 Jun 2022 | ₹88.03 | ₹87.01 |
| 05 Nov 2022 | ₹104.74 | ₹103.07 |
| 23 Mar 2023 | ₹99.63 | ₹97.16 |
| 09 Aug 2023 | ₹114.31 | ₹111.70 |
| 25 Dec 2023 | ₹123.34 | ₹121.46 |
| 12 May 2024 | ₹126.32 | ₹125.48 |
| 27 Sep 2024 | ₹149.53 | ₹148.94 |
| 12 Feb 2025 | ₹133.34 | ₹131.11 |
| 01 Jul 2025 | ₹147.19 | ₹145.32 |
| 16 Nov 2025 | ₹149.25 | ₹147.41 |
| 04 Apr 2026 | ₹129.38 | ₹129.22 |
| 20 Aug 2026 | ₹137.73 | ₹137.86 |
| Metric | UTI · Regular NAV ₹13.97 Very High risk ★★★☆☆ | Category median Index Funds · 366 funds |
|---|---|---|
| -4.57% | +5.43% | |
| +6.95% | +8.41% | |
| — | +8.95% | |
| — | +11.28% | |
| +7.29% | +7.40% | |
| +5.63% | — | |
| +11.37% | +11.37% | |
| — | +13.00% | |
| — | +11.07% | |
| Risk | ||
| 13.21% | 13.88% | |
| 0.03 | 0.25 | |
| 0.05 | 0.35 | |
| -16.10% | -16.66% | |
| Nifty 50 | — | |
| -0.87% | +0.30% | |
| 0.99 | 1.00 | |
| 98.3% | 101.3% | |
| 103.8% | 98.8% | |
| 0.32% | 0.96% | |
| ₹194.78Cr | ₹182.17Cr | |
| None | — | |
| None | — | |
| ₹2.02K | — | |
| ₹1.00K | — | |
| 12% | 35% | |
| Sharwan Kumar Goyal | — | |
| 01 Feb 2022 | — | |
| 30 | — | |
| 63.5% | — | |
| 0.4% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.